<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967173</url>
  </required_header>
  <id_info>
    <org_study_id>AsthmaNet 006</org_study_id>
    <secondary_id>1U10HL098115</secondary_id>
    <nct_id>NCT01967173</nct_id>
  </id_info>
  <brief_title>Best African American Response to Asthma Drugs</brief_title>
  <acronym>BARD</acronym>
  <official_title>Best African American Response to Asthma Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find the best asthma treatment to add for Blacks who have
      asthma that is not well controlled on a low dose of inhaled steroid. This study will also try
      to find out if Black adults and children differ in how they respond to the medications used
      in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BARD is a 66 week prospective, randomized, double-blind, crossover trial in Blacks
      (individuals who self-report Black ancestry) who have inadequately controlled asthma while
      taking low-dose inhaled corticosteroids (ICS). BARD will examine the efficacy of increasing
      the dose of ICS with or without the addition of a long-acting beta agonist (LABA) to
      determine whether individual patients respond better to one treatment than another and, if
      so, whether the responses are different for children and adults or if they are related to
      genetic ancestry.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">July 1, 2017</completion_date>
  <primary_completion_date type="Actual">July 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is a composite measure that uses exacerbations, asthma control days during the last 12 of 14 weeks of a treatment regimen, and percent predicted FEV1 at the end of a treatment regimen.</measure>
    <time_frame>The last 12 weeks of each 14-week treatment period</time_frame>
    <description>This composite outcome uses a hierarchical method to ascertain differences in asthma control. For each participant, treatments are first compared to see if they differ in terms of exacerbations. If one treatment results in fewer exacerbations than another, it is deemed the superior treatment and no further comparisons are made. If treatment superiority cannot be assigned by exacerbations, then they are compared by asthma control days (ACDs). If one treatment yields at least 31 annualized ACDs more than another, it is deemed the superior treatment. If treatment superiority still cannot be assigned by ACDs, then they are compared by percent predicted FEV1 at the end of a treatment period. If one treatment yields at least 5% greater FEV1 than another, it is deemed the superior treatment. If treatment superiority cannot be assigned by exacerbations, ACDs or FEV1, then that participant is classified as having no differential response.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">574</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flovent Diskus® 100 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 250/50 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Flovent Diskus® 250 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flovent Diskus® 250 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 100 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 500 mcg, followed by Advair Diskus® 250/50 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Flovent Diskus® 500 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flovent Diskus® 500 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 500 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flovent Diskus® 100 mcg</intervention_name>
    <description>Flovent is an ICS</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flovent Diskus® 250 mcg</intervention_name>
    <description>Flovent is an ICS</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_label>Crossover sequence 6</arm_group_label>
    <arm_group_label>Crossover sequence 7</arm_group_label>
    <arm_group_label>Crossover sequence 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flovent Diskus® 500 mcg</intervention_name>
    <description>Flovent is an ICS</description>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_label>Crossover sequence 6</arm_group_label>
    <arm_group_label>Crossover sequence 7</arm_group_label>
    <arm_group_label>Crossover sequence 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advair Diskus® 100/50 mcg</intervention_name>
    <description>Advair is an ICS/LABA combination</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_label>Crossover sequence 6</arm_group_label>
    <arm_group_label>Crossover sequence 7</arm_group_label>
    <arm_group_label>Crossover sequence 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advair Diskus® 250/50 mcg</intervention_name>
    <description>Advair is an ICS/LABA combination</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_label>Crossover sequence 6</arm_group_label>
    <arm_group_label>Crossover sequence 7</arm_group_label>
    <arm_group_label>Crossover sequence 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Individuals who self-report Black ancestry (with at least 1 Black grandparent).

          2. Able to perform reproducible spirometry according to ATS criteria.

          3. Clinical history consistent with asthma.

          4. Baseline FEV1≥40% of predicted and/or post-bronchodilator FEV1≥40% of predicted.

          5. Asthma confirmed either by: (1) Beta-agonist reversibility to 4 puffs albuterol ≥ 12%
             OR (2) PC20FEV1 ≤ 16 mg/ml OR (3) an absolute relative change in %predicted FEV1 of ≥
             12% over two measurements documented by repeat spirogram over the previous year

          6. Either: A) inadequately controlled on low-, medium- or high-dose ICS monotherapy, or
             low- or medium-dose ICS/LABA, or B) well-controlled on medium- or high-dose ICS
             monotherapy, or low-, medium- or high-dose ICS/LABA. Inadequate asthma control will be
             defined as an ACT/c-ACT score &lt;20; well-controlled asthma will be defined as an
             ACT/c-ACT score ≥20.

          7. Stable asthma controller therapy dose (ICS or ICS/LABA) for the 2 weeks prior to
             enrollment.

          8. Non-smoker (total lifetime smoking history &lt; 5 pack-years if &lt;18, or &lt;10 pack-years if
             ≥18 years of age; no smoking for at least 1 year).

          9. For participants ≥18 years of age: Ability to provide informed consent. For
             participants under 18 years of age: Ability to provide verbal or written assent and
             ability of parent to provide informed consent.

        Exclusion Criteria:

          1. Medical contraindication to LABA or history of adverse reactions to ICS or LABA
             preparations or any of their ingredients.

          2. Current or prior use of medications known to significantly interact with
             corticosteroid disposition within the two-week period preceding enrollment.

          3. Unwilling to provide a blood sample for DNA extraction and genetic analysis.

          4. Major medical problems prohibiting study participation, i.e. presence of chronic or
             active lung disease other than asthma or history of unstable significant medical
             illness other than asthma, including thyroid disease, diabetes mellitus, Cushing's
             disease, Addison's disease, hepatic disease, or concurrent medical problems that could
             require oral corticosteroids during the study or that would place the participant at
             increased risk.

          5. Systemic corticosteroid treatment for any condition within 4 weeks of enrollment or
             more than five courses of systemic corticosteroids in the past year.

          6. History of a life-threatening asthma exacerbation requiring intubation, mechanical
             ventilation, or resulting in a hypoxic seizure within the last 2 years.

          7. History of a respiratory tract infection within 4 weeks of enrollment.

          8. If a female of child-bearing potential, failure to practice abstinence or use an
             acceptable birth control method.

          9. Pregnancy or lactation or planning to get pregnant during the course of the trial.

         10. Receiving hyposensitization therapy other than an established maintenance regimen
             defined as a continuous regimen for ≥ 3 months prior to enrollment.

         11. Participation in an intervention trial or use of investigative drugs in the past 30
             days or plans to enroll in such a trial during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Busse, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona College of Medicine</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital &amp; Research Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital, Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Urban Population Health</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://asthmanetresearch.org/</url>
    <description>AsthmaNet</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2013</study_first_submitted>
  <study_first_submitted_qc>October 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2013</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>dave mauger</investigator_full_name>
    <investigator_title>Principal Investigator, AsthmaNet Data Coordinating Center</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Fluticasone</keyword>
  <keyword>Salmeterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

